Ciclosporin ophthalmic - Novaliq

Drug Profile

Ciclosporin ophthalmic - Novaliq

Alternative Names: CyclAsol; Cyclosol; Cyclosporine; Cyclosporine-A

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novaliq
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 05 Jan 2017 Top-line safety and efficacy results from the phase II trial in Dry eyes released by Novaliq
  • 15 Dec 2016 Biomarkers information updated
  • 01 Sep 2016 Novaliq completes a phase II trial in Dry eyes in USA (Ophthalmic) (NCT02617667)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top